论文部分内容阅读
据美国研究者报道，CeltrixPharmaceuti－cals公司的生长调节素-1结合蛋白一3（so－matomedin－1bindingprotein－3，商品名Soma－toKine）能够显著降低I型糖尿病患者的胰岛素耐受性。结果表明，在这一Ⅱ期临床研究中，12例这类病人接受本品2mg/g和安慰剂，以交叉给药方式通过?
According to U.S. researchers, Celtrix Pharmaceuti-cals’s somatotrophin-1 binding protein-3 (Soma-toKine) can significantly reduce insulin resistance in patients with type I diabetes. The results showed that in this Phase Ⅱ clinical study, 12 patients receiving this product 2mg / g and placebo to cross the way through?